Carotuximab, identified as TRC105 and DE-122, represents a unique antibody-drug conjugate construct currently under investigation for combating various oncological diseases. This specific molecule binds to a unique https://alvinvvob014548.pointblog.net/carotuximab-trc105-de-122-a-deep-dive-92629442